



# Essai Clinique

Généré le 18 mai 2024 à partir de

Titre	A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer
Protocole ID	DESTINY-Breast11
ClinicalTrials.gov ID	<a href="#">NCT05113251</a>
Type(s) de cancer	Sein
Phase	Phase III
Type étude	Clinique
Médicament	Trastuzumab Deruxtecan (T-DXd) en monothérapie versus T-DXd suivi de THP versus ddAC-THP
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
Ville	
Investigateur principal	Dr Jean-François Boileau
Coordonnateur	Gladys El Helou 514-340-8222 poste 26581
Statut	Actif en recrutement
But étude	The target population of interest in this study is participants with high-risk HER2-positive early-stage breast cancer. The purpose of this study is to determine the efficacy and safety of T-DXd neoadjuvant therapy. Participants will be randomised to one of 3 arms: T-DXd monotherapy (Arm A), T-DXd followed by THP (Arm B), or ddAC-THP (Arm C).
Critères d'éligibilité	<ul style="list-style-type: none"><li>• Patients must be at least 18 years of age.</li><li>• Histologically documented HER2-positive early breast cancer (EBC) participants, including clinical stage at presentation (based on mammogram or breast MRI assessment): T0-4 (inclusive of inflammatory breast cancer), N1-3, M0 or <math>\geq</math> T3, N0, M0 as determined by the AJCC staging system, 8th edition</li><li>• ECOG performance status of 0 or 1 at randomization</li></ul>
Critères d'exclusion	<ul style="list-style-type: none"><li>• prior history of invasive breast cancer</li><li>• stage IV breast cancer (determined by AJCC staging system)</li><li>• any primary malignancy within 3 years (except resected non-melanoma skin cancer, curatively treated in situ disease)</li><li>• history of DCIS (except those treated with mastectomy &gt;5 years prior to current diagnosis)</li><li>• History of, or current, ILD/pneumonitis</li><li>• Prior systemic therapy for the treatment of breast cancer</li><li>• Previous treatment with anthracyclines, cyclophosphamide or taxanes for any malignancy</li></ul>